Effectiveness and safety of the direct oral anticoagulant in acute distal deep vein thrombosis: From the prospective multicenter observational study, J'xactly, in Japan.

IF 1.6 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Phlebology Pub Date : 2023-02-01 DOI:10.1177/02683555221141310

Makoto Mo, Ikuo Fukuda, Mashio Nakamura, Norikazu Yamada, Morimasa Takayama, Hideaki Maeda, Takeshi Yamashita, Takanori Ikeda, Tsutomu Yamazaki, Yasuo Okumura, Atsushi Hirayama

{"title":"Effectiveness and safety of the direct oral anticoagulant in acute distal deep vein thrombosis: From the prospective multicenter observational study, J'xactly, in Japan.","authors":"Makoto Mo, Ikuo Fukuda, Mashio Nakamura, Norikazu Yamada, Morimasa Takayama, Hideaki Maeda, Takeshi Yamashita, Takanori Ikeda, Tsutomu Yamazaki, Yasuo Okumura, Atsushi Hirayama","doi":"10.1177/02683555221141310","DOIUrl":null,"url":null,"abstract":"Objectives: We assessed the effectiveness and safety of rivaroxaban in patients with isolated distal deep vein thrombosis (IDDVT).Methods: Symptomatic venous thromboembolism (VTE) and major bleeding were assessed.Results: Of 1016 patients with acute symptomatic/asymptomatic DVT and/or pulmonary embolism treated with rivaroxaban, 288 had IDDVT and 294 had proximal DVT (pDVT). The IDDVT group had fewer patients on the higher rivaroxaban dose (30 mg/day) (42.7% vs. 66.0%) and a shorter treatment duration (135.5 vs 369.5 days) than the pDVT group. VTE recurrence occurred in 14 and 11 patients with IDDVT and pDVT, respectively (2.89% vs. 2.29% per patient-year; p = 0.534). Major bleeding was less frequent in the IDDVT group (1.55% vs. 4.53% per patient-year; p = 0.044). Comparable effectiveness and safety were observed with 15 and 30 mg/day rivaroxaban in the IDDVT group.Conclusions: Short-term, low-dose rivaroxaban seems safe and effective for IDDVT treatment.","PeriodicalId":20139,"journal":{"name":"Phlebology","volume":"38 1","pages":"4-15"},"PeriodicalIF":1.6000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phlebology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02683555221141310","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: We assessed the effectiveness and safety of rivaroxaban in patients with isolated distal deep vein thrombosis (IDDVT).

Methods: Symptomatic venous thromboembolism (VTE) and major bleeding were assessed.

Results: Of 1016 patients with acute symptomatic/asymptomatic DVT and/or pulmonary embolism treated with rivaroxaban, 288 had IDDVT and 294 had proximal DVT (pDVT). The IDDVT group had fewer patients on the higher rivaroxaban dose (30 mg/day) (42.7% vs. 66.0%) and a shorter treatment duration (135.5 vs 369.5 days) than the pDVT group. VTE recurrence occurred in 14 and 11 patients with IDDVT and pDVT, respectively (2.89% vs. 2.29% per patient-year; p = 0.534). Major bleeding was less frequent in the IDDVT group (1.55% vs. 4.53% per patient-year; p = 0.044). Comparable effectiveness and safety were observed with 15 and 30 mg/day rivaroxaban in the IDDVT group.

Conclusions: Short-term, low-dose rivaroxaban seems safe and effective for IDDVT treatment.

查看原文本刊更多论文

直接口服抗凝剂治疗急性远端深静脉血栓的有效性和安全性:来自日本的前瞻性多中心观察性研究

目的:评估利伐沙班治疗孤立性远端深静脉血栓形成(IDDVT)的有效性和安全性。方法:对症状性静脉血栓栓塞(VTE)和大出血进行评估。结果:1016例急性有症状/无症状DVT和/或肺栓塞患者接受利伐沙班治疗，288例发生IDDVT, 294例发生近端DVT (pDVT)。与pDVT组相比，IDDVT组使用高剂量利伐沙班(30mg /天)的患者较少(42.7% vs 66.0%)，治疗时间较短(135.5 vs 369.5天)。IDDVT和pDVT患者分别有14例和11例静脉血栓栓塞复发(2.89% vs 2.29% /患者-年);P = 0.534)。IDDVT组大出血发生率较低(1.55% vs 4.53% /患者年);P = 0.044)。在IDDVT组中观察到15和30 mg/天利伐沙班的有效性和安全性相当。结论:短期小剂量利伐沙班治疗IDDVT安全有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phlebology 医学-外周血管病

CiteScore

3.30

自引率

11.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The leading scientific journal devoted entirely to venous disease, Phlebology is the official journal of several international societies devoted to the subject. It publishes the results of high quality studies and reviews on any factor that may influence the outcome of patients with venous disease. This journal provides authoritative information about all aspects of diseases of the veins including up to the minute reviews, original articles, and short reports on the latest treatment procedures and patient outcomes to help medical practitioners, allied health professionals and scientists stay up-to-date on developments. Print ISSN: 0268-3555